Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosensors CE marks BioMatrix Flex

This article was originally published in Clinica

Executive Summary

Biosensors International has CE marked a new version of its BioMatrix drug-eluting stent (DES). Called BioMatrix Flex, the device incorporates Biosensors' abluminal biodegradable poly-lactic acid polymer, and the antirestenotic drug Biolimus A9. The DES will be launched "over the coming months", the firm said. Singapore-based Biosensors CE marked the first version of BioMatrix in January 2008, and the smaller-diameter (2.25mm) version in March 2009. The company has also gained French reimbursement approval for the first-generation form of BioMatrix. The stent will be available throughout France from January 28 to patients with coronary artery disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel